nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketamine—TACR1—cranial nerve—amyotrophic lateral sclerosis	0.0284	0.069	CbGeAlD
Ketamine—GRIN2C—nerve—amyotrophic lateral sclerosis	0.0192	0.0467	CbGeAlD
Ketamine—TACR1—peripheral nervous system—amyotrophic lateral sclerosis	0.0187	0.0454	CbGeAlD
Ketamine—GRIN2B—nerve—amyotrophic lateral sclerosis	0.0152	0.0369	CbGeAlD
Ketamine—TACR1—nerve—amyotrophic lateral sclerosis	0.0146	0.0354	CbGeAlD
Ketamine—GRIN2C—hindbrain—amyotrophic lateral sclerosis	0.0144	0.035	CbGeAlD
Ketamine—GRIN2D—hindbrain—amyotrophic lateral sclerosis	0.0134	0.0325	CbGeAlD
Ketamine—GRIN2A—nerve—amyotrophic lateral sclerosis	0.0133	0.0323	CbGeAlD
Ketamine—GRIN1—hindbrain—amyotrophic lateral sclerosis	0.0119	0.029	CbGeAlD
Ketamine—GRIN2B—hindbrain—amyotrophic lateral sclerosis	0.0114	0.0276	CbGeAlD
Ketamine—GRIN2A—hindbrain—amyotrophic lateral sclerosis	0.00995	0.0242	CbGeAlD
Ketamine—GRIN2C—brainstem—amyotrophic lateral sclerosis	0.00826	0.02	CbGeAlD
Ketamine—OPRM1—nerve—amyotrophic lateral sclerosis	0.00808	0.0196	CbGeAlD
Ketamine—GRIN2D—brainstem—amyotrophic lateral sclerosis	0.00768	0.0186	CbGeAlD
Ketamine—GRIN1—brainstem—amyotrophic lateral sclerosis	0.00684	0.0166	CbGeAlD
Ketamine—GRIN2B—brainstem—amyotrophic lateral sclerosis	0.00653	0.0158	CbGeAlD
Ketamine—TACR1—brainstem—amyotrophic lateral sclerosis	0.00626	0.0152	CbGeAlD
Ketamine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00592	0.0144	CbGeAlD
Ketamine—GRIN2C—medulla oblongata—amyotrophic lateral sclerosis	0.00576	0.014	CbGeAlD
Ketamine—GRIN2A—brainstem—amyotrophic lateral sclerosis	0.00571	0.0138	CbGeAlD
Ketamine—DRD2—nerve—amyotrophic lateral sclerosis	0.00539	0.0131	CbGeAlD
Ketamine—GRIN2D—medulla oblongata—amyotrophic lateral sclerosis	0.00535	0.013	CbGeAlD
Ketamine—GRIN2D—spinal cord—amyotrophic lateral sclerosis	0.00477	0.0116	CbGeAlD
Ketamine—GRIN2C—nervous system—amyotrophic lateral sclerosis	0.00433	0.0105	CbGeAlD
Ketamine—GRIN1—spinal cord—amyotrophic lateral sclerosis	0.00425	0.0103	CbGeAlD
Ketamine—GRIN2C—central nervous system—amyotrophic lateral sclerosis	0.00417	0.0101	CbGeAlD
Ketamine—GRIN2C—cerebellum—amyotrophic lateral sclerosis	0.00407	0.00988	CbGeAlD
Ketamine—GRIN2B—spinal cord—amyotrophic lateral sclerosis	0.00406	0.00985	CbGeAlD
Ketamine—DRD2—hindbrain—amyotrophic lateral sclerosis	0.00404	0.0098	CbGeAlD
Ketamine—GRIN2D—nervous system—amyotrophic lateral sclerosis	0.00402	0.00976	CbGeAlD
Ketamine—GRIN2A—medulla oblongata—amyotrophic lateral sclerosis	0.00398	0.00966	CbGeAlD
Ketamine—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.00396	0.151	CcSEcCtD
Ketamine—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.00396	0.151	CcSEcCtD
Ketamine—TACR1—spinal cord—amyotrophic lateral sclerosis	0.00389	0.00944	CbGeAlD
Ketamine—GRIN2D—central nervous system—amyotrophic lateral sclerosis	0.00387	0.0094	CbGeAlD
Ketamine—GRIN2D—cerebellum—amyotrophic lateral sclerosis	0.00378	0.00919	CbGeAlD
Ketamine—GRIN3A—nervous system—amyotrophic lateral sclerosis	0.00378	0.00918	CbGeAlD
Ketamine—GRIN3A—central nervous system—amyotrophic lateral sclerosis	0.00364	0.00884	CbGeAlD
Ketamine—GRIN1—nervous system—amyotrophic lateral sclerosis	0.00358	0.0087	CbGeAlD
Ketamine—GRIN2A—spinal cord—amyotrophic lateral sclerosis	0.00355	0.00861	CbGeAlD
Ketamine—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00352	0.134	CcSEcCtD
Ketamine—OPRM1—brainstem—amyotrophic lateral sclerosis	0.00347	0.00842	CbGeAlD
Ketamine—GRIN1—central nervous system—amyotrophic lateral sclerosis	0.00345	0.00838	CbGeAlD
Ketamine—GRIN2B—nervous system—amyotrophic lateral sclerosis	0.00342	0.0083	CbGeAlD
Ketamine—GRIN1—cerebellum—amyotrophic lateral sclerosis	0.00337	0.00819	CbGeAlD
Ketamine—GRIN2C—brain—amyotrophic lateral sclerosis	0.00331	0.00803	CbGeAlD
Ketamine—GRIN2B—central nervous system—amyotrophic lateral sclerosis	0.00329	0.00799	CbGeAlD
Ketamine—TACR1—nervous system—amyotrophic lateral sclerosis	0.00328	0.00796	CbGeAlD
Ketamine—GRIN2B—cerebellum—amyotrophic lateral sclerosis	0.00322	0.00781	CbGeAlD
Ketamine—TACR1—central nervous system—amyotrophic lateral sclerosis	0.00316	0.00766	CbGeAlD
Ketamine—GRIN2D—brain—amyotrophic lateral sclerosis	0.00307	0.00746	CbGeAlD
Ketamine—GRIN2A—nervous system—amyotrophic lateral sclerosis	0.00299	0.00725	CbGeAlD
Ketamine—GRIN3A—brain—amyotrophic lateral sclerosis	0.00289	0.00701	CbGeAlD
Ketamine—GRIN2A—central nervous system—amyotrophic lateral sclerosis	0.00288	0.00698	CbGeAlD
Ketamine—GRIN2A—cerebellum—amyotrophic lateral sclerosis	0.00281	0.00683	CbGeAlD
Ketamine—GRIN1—brain—amyotrophic lateral sclerosis	0.00274	0.00665	CbGeAlD
Ketamine—OPRD1—nervous system—amyotrophic lateral sclerosis	0.00266	0.00647	CbGeAlD
Ketamine—GRIN2B—brain—amyotrophic lateral sclerosis	0.00261	0.00634	CbGeAlD
Ketamine—OPRD1—central nervous system—amyotrophic lateral sclerosis	0.00257	0.00623	CbGeAlD
Ketamine—OPRK1—nervous system—amyotrophic lateral sclerosis	0.00255	0.0062	CbGeAlD
Ketamine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00254	0.00616	CbGeAlD
Ketamine—TACR1—brain—amyotrophic lateral sclerosis	0.00251	0.00608	CbGeAlD
Ketamine—OPRK1—central nervous system—amyotrophic lateral sclerosis	0.00246	0.00597	CbGeAlD
Ketamine—OPRK1—cerebellum—amyotrophic lateral sclerosis	0.0024	0.00583	CbGeAlD
Ketamine—DRD2—brainstem—amyotrophic lateral sclerosis	0.00231	0.00562	CbGeAlD
Ketamine—GRIN2A—brain—amyotrophic lateral sclerosis	0.00228	0.00555	CbGeAlD
Ketamine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00217	0.0826	CcSEcCtD
Ketamine—OPRM1—spinal cord—amyotrophic lateral sclerosis	0.00216	0.00523	CbGeAlD
Ketamine—OPRD1—brain—amyotrophic lateral sclerosis	0.00204	0.00494	CbGeAlD
Ketamine—OPRK1—brain—amyotrophic lateral sclerosis	0.00195	0.00474	CbGeAlD
Ketamine—OPRM1—nervous system—amyotrophic lateral sclerosis	0.00182	0.00441	CbGeAlD
Ketamine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00177	0.0043	CbGeAlD
Ketamine—OPRM1—central nervous system—amyotrophic lateral sclerosis	0.00175	0.00425	CbGeAlD
Ketamine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0582	CcSEcCtD
Ketamine—OPRM1—brain—amyotrophic lateral sclerosis	0.00139	0.00337	CbGeAlD
Ketamine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0511	CcSEcCtD
Ketamine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00133	0.00323	CbGeAlD
Ketamine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00128	0.00311	CbGeAlD
Ketamine—DRD2—nervous system—amyotrophic lateral sclerosis	0.00121	0.00294	CbGeAlD
Ketamine—DRD2—central nervous system—amyotrophic lateral sclerosis	0.00117	0.00283	CbGeAlD
Ketamine—DRD2—cerebellum—amyotrophic lateral sclerosis	0.00114	0.00277	CbGeAlD
Ketamine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00113	0.0431	CcSEcCtD
Ketamine—ABCB1—embryo—amyotrophic lateral sclerosis	0.00109	0.00265	CbGeAlD
Ketamine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00106	0.0406	CcSEcCtD
Ketamine—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.00105	0.00255	CbGeAlD
Ketamine—Shock—Riluzole—amyotrophic lateral sclerosis	0.00105	0.04	CcSEcCtD
Ketamine—SLC6A2—brain—amyotrophic lateral sclerosis	0.00102	0.00247	CbGeAlD
Ketamine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0387	CcSEcCtD
Ketamine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000995	0.0379	CcSEcCtD
Ketamine—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.00098	0.00238	CbGeAlD
Ketamine—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000944	0.00229	CbGeAlD
Ketamine—DRD2—brain—amyotrophic lateral sclerosis	0.000927	0.00225	CbGeAlD
Ketamine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000925	0.0353	CcSEcCtD
Ketamine—Pain—Riluzole—amyotrophic lateral sclerosis	0.00091	0.0347	CcSEcCtD
Ketamine—PTGS1—nervous system—amyotrophic lateral sclerosis	0.000886	0.00215	CbGeAlD
Ketamine—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000853	0.00207	CbGeAlD
Ketamine—CYP2C8—brain—amyotrophic lateral sclerosis	0.000835	0.00203	CbGeAlD
Ketamine—CYP2B6—brain—amyotrophic lateral sclerosis	0.000749	0.00182	CbGeAlD
Ketamine—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.00074	0.0018	CbGeAlD
Ketamine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000713	0.00173	CbGeAlD
Ketamine—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000697	0.00169	CbGeAlD
Ketamine—PTGS1—brain—amyotrophic lateral sclerosis	0.000677	0.00164	CbGeAlD
Ketamine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000677	0.0258	CcSEcCtD
Ketamine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000671	0.0256	CcSEcCtD
Ketamine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00067	0.0256	CcSEcCtD
Ketamine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000632	0.0241	CcSEcCtD
Ketamine—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000622	0.00151	CbGeAlD
Ketamine—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000524	0.00127	CbGeAlD
Ketamine—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000505	0.00122	CbGeAlD
Ketamine—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000493	0.0012	CbGeAlD
Ketamine—ABCB1—brain—amyotrophic lateral sclerosis	0.000401	0.000972	CbGeAlD
Ketamine—OPRD1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000209	0.000372	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000208	0.00037	CbGpPWpGaD
Ketamine—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000202	0.000359	CbGpPWpGaD
Ketamine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000201	0.000359	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000201	0.000358	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.0002	0.000356	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000199	0.000355	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000199	0.000355	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000199	0.000354	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000199	0.000354	CbGpPWpGaD
Ketamine—CYP2B6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000199	0.000354	CbGpPWpGaD
Ketamine—OPRM1—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000198	0.000352	CbGpPWpGaD
Ketamine—CYP2B6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000196	0.000349	CbGpPWpGaD
Ketamine—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.00019	0.000339	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.00019	0.000338	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000188	0.000335	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000186	0.000331	CbGpPWpGaD
Ketamine—OPRK1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000186	0.000331	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000183	0.000326	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000182	0.000325	CbGpPWpGaD
Ketamine—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000182	0.000323	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00017	0.000302	CbGpPWpGaD
Ketamine—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000168	0.000299	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000166	0.000296	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000166	0.000296	CbGpPWpGaD
Ketamine—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000166	0.000295	CbGpPWpGaD
Ketamine—TACR1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000162	0.000288	CbGpPWpGaD
Ketamine—OPRD1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000161	0.000287	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000159	0.000284	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000158	0.000282	CbGpPWpGaD
Ketamine—OPRM1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000157	0.00028	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000155	0.000276	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000154	0.000274	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000152	0.000271	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000152	0.000271	CbGpPWpGaD
Ketamine—DRD2—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.00015	0.000267	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000148	0.000263	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000147	0.000262	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000144	0.000257	CbGpPWpGaD
Ketamine—OPRK1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000142	0.000252	CbGpPWpGaD
Ketamine—GRIN1—Axon guidance—MMP9—amyotrophic lateral sclerosis	0.000141	0.000251	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000141	0.00025	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000139	0.000248	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000139	0.000248	CbGpPWpGaD
Ketamine—GRIN2B—Axon guidance—MMP9—amyotrophic lateral sclerosis	0.000138	0.000245	CbGpPWpGaD
Ketamine—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000137	0.000244	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000137	0.000243	CbGpPWpGaD
Ketamine—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000135	0.00024	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000132	0.000235	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000131	0.000234	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00013	0.000231	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.00013	0.000231	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000129	0.00023	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000129	0.00023	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000129	0.000229	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000129	0.000229	CbGpPWpGaD
Ketamine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000129	0.000229	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000128	0.000228	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000128	0.000227	CbGpPWpGaD
Ketamine—GRIN1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	0.000127	0.000226	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000124	0.00022	CbGpPWpGaD
Ketamine—GRIN2B—Axon guidance—VEGFA—amyotrophic lateral sclerosis	0.000124	0.00022	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000122	0.000217	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000122	0.000217	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000122	0.000217	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.00012	0.000214	CbGpPWpGaD
Ketamine—OPRM1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.00012	0.000213	CbGpPWpGaD
Ketamine—DRD2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000119	0.000212	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000118	0.00021	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000117	0.000209	CbGpPWpGaD
Ketamine—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000117	0.000208	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000116	0.000206	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000113	0.000202	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000112	0.0002	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000112	0.0002	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000112	0.0002	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000112	0.000199	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000111	0.000198	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—DAO—amyotrophic lateral sclerosis	0.00011	0.000196	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00011	0.000195	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00011	0.000195	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000109	0.000195	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000107	0.00019	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000105	0.000187	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000105	0.000187	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000105	0.000186	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000103	0.000183	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000103	0.000183	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000103	0.000183	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	0.000101	0.00018	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	0.000101	0.000179	CbGpPWpGaD
Ketamine—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	9.95e-05	0.000177	CbGpPWpGaD
Ketamine—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	9.95e-05	0.000177	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	9.94e-05	0.000177	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	9.83e-05	0.000175	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.83e-05	0.000175	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—MMP9—amyotrophic lateral sclerosis	9.82e-05	0.000175	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	9.78e-05	0.000174	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	9.77e-05	0.000174	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	9.59e-05	0.000171	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.54e-05	0.00017	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	9.46e-05	0.000168	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	9.37e-05	0.000167	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	9.31e-05	0.000166	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	9.18e-05	0.000164	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	9.12e-05	0.000162	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	9.06e-05	0.000161	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	9.05e-05	0.000161	CbGpPWpGaD
Ketamine—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.02e-05	0.000161	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	8.97e-05	0.00016	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.91e-05	0.000159	CbGpPWpGaD
Ketamine—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.9e-05	0.000158	CbGpPWpGaD
Ketamine—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	8.87e-05	0.000158	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	8.82e-05	0.000157	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.69e-05	0.000155	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	8.41e-05	0.00015	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	8.4e-05	0.00015	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	8.38e-05	0.000149	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PLB1—amyotrophic lateral sclerosis	8.34e-05	0.000148	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	8.31e-05	0.000148	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	8.31e-05	0.000148	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	8.28e-05	0.000147	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	8.28e-05	0.000147	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.22e-05	0.000146	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	8.11e-05	0.000144	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.09e-05	0.000144	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8e-05	0.000142	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	7.81e-05	0.000139	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.7e-05	0.000137	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	7.69e-05	0.000137	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	7.58e-05	0.000135	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	7.56e-05	0.000135	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	7.4e-05	0.000132	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.26e-05	0.000129	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.22e-05	0.000129	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.17e-05	0.000128	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	7.06e-05	0.000126	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	6.98e-05	0.000124	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	6.94e-05	0.000124	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	6.91e-05	0.000123	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	6.91e-05	0.000123	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.88e-05	0.000122	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	6.76e-05	0.00012	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.75e-05	0.00012	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.68e-05	0.000119	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	6.51e-05	0.000116	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	6.48e-05	0.000115	CbGpPWpGaD
Ketamine—DRD2—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	6.44e-05	0.000115	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6.37e-05	0.000113	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.33e-05	0.000113	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	6.32e-05	0.000113	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	6.32e-05	0.000112	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.3e-05	0.000112	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	6.15e-05	0.000109	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	6.14e-05	0.000109	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.03e-05	0.000107	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.93e-05	0.000106	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.89e-05	0.000105	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.88e-05	0.000105	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	5.74e-05	0.000102	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.71e-05	0.000102	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	5.68e-05	0.000101	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.54e-05	9.86e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	5.53e-05	9.84e-05	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	5.5e-05	9.78e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.35e-05	9.53e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	5.35e-05	9.52e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	5.3e-05	9.44e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	5.26e-05	9.37e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.18e-05	9.22e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.16e-05	9.19e-05	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.14e-05	9.16e-05	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	5.12e-05	9.12e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.1e-05	9.08e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	5e-05	8.9e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.89e-05	8.71e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.88e-05	8.69e-05	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.86e-05	8.65e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.85e-05	8.64e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.83e-05	8.6e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	4.66e-05	8.3e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.65e-05	8.28e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.55e-05	8.11e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.45e-05	7.92e-05	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.36e-05	7.77e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.36e-05	7.77e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	4.35e-05	7.75e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.33e-05	7.7e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.29e-05	7.64e-05	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	4.15e-05	7.39e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.1e-05	7.3e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.09e-05	7.28e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.06e-05	7.22e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.99e-05	7.11e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.97e-05	7.07e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.86e-05	6.88e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	3.79e-05	6.74e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.76e-05	6.7e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.63e-05	6.45e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	3.5e-05	6.22e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.4e-05	6.05e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.38e-05	6.01e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	3.37e-05	5.99e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.34e-05	5.95e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.31e-05	5.89e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.3e-05	5.88e-05	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.3e-05	5.87e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.12e-05	5.56e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.11e-05	5.54e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.9e-05	5.16e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.88e-05	5.12e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	2.87e-05	5.11e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.79e-05	4.97e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.75e-05	4.89e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.74e-05	4.87e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.72e-05	4.85e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.64e-05	4.7e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	2.57e-05	4.57e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.56e-05	4.55e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.54e-05	4.52e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.5e-05	4.46e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.46e-05	4.38e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.4e-05	4.27e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.34e-05	4.17e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.31e-05	4.11e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.3e-05	4.1e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	2.17e-05	3.87e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.16e-05	3.84e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.15e-05	3.83e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.15e-05	3.82e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.11e-05	3.76e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.03e-05	3.61e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.89e-05	3.37e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.86e-05	3.31e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.82e-05	3.24e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	1.77e-05	3.15e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.76e-05	3.13e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.63e-05	2.9e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.63e-05	2.9e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.54e-05	2.75e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.54e-05	2.74e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.49e-05	2.65e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.42e-05	2.52e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.38e-05	2.46e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.38e-05	2.45e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.3e-05	2.31e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.21e-05	2.16e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.17e-05	2.08e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.04e-05	1.86e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.99e-06	1.42e-05	CbGpPWpGaD
